Synergistic anti‐myeloma activity of the proteasome inhibitor marizomib and the IMiD® immunomodulatory drug pomalidomide

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|171|5|798-812

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.171, Iss.5, 2015-12, pp. : 798-812

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 2, 2018-01 ,pp. : 271-275

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (NPI‐0052‐107): final study results

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 1, 2018-01 ,pp. : 41-51

John Wiley & Sons Inc

Access to resources Recommend Favorite

Unique anti‐myeloma activity by thiazolidine‐2,4‐dione compounds with Pim inhibiting activity

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 2, 2018-01 ,pp. : 246-258

John Wiley & Sons Inc

Access to resources Recommend Favorite

Valproic acid, an anti-epileptic drug and a histone deacetylase inhibitor, in combination with proteasome inhibitors exerts antiproliferative, pro-apoptotic and chemosensitizing effects in human colorectal cancer cells: Underlying molecular mechanisms

By      

International Journal of Molecular Medicine, Vol. 34, Iss. 2, 2014-01 ,pp. : 513-532

Spandidos Publications

Access to resources Recommend Favorite

Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs

By          

International Journal of Molecular Medicine, Vol. 29, Iss. 1, 2012-01 ,pp. : 102-106

Spandidos Publications

Access to resources Recommend Favorite